Effectiveness of physiotherapy modalities on persisting dyspnoea in long COVID: A systematic review and meta-analysis. (2025)
“PR probably performs in the same way in both COPD and long-covid”
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group and compared with another group, not randomised (very low certainty): 4 of 6 findings are C.
5 outcomes rated · see each below
Both together: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 4 findings, all C.
6 outcomes rated · see each below
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: For long COVID, physical therapy / physiotherapy might help some people, but research can’t show it yet. For long COVID and ME/CFS studied together, physical therapy / physiotherapy might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · 5 weeks · first 3 visits (few people)
Pain improved.
The evidence is very uncertain about the effect of Physical therapy / physiotherapy on pain in long COVID. Improvement · very low certainty C
Combination: CBT and psychotherapy + Physical therapy / physiotherapy1 in the study
Case Report: Overlap Between Long COVID and Functional Neurological Disorders. (2021): chest pain, no clear difference.
Shown, not counted: physical therapy / physiotherapy was given together with other treatments.
Musculoskeletal physiotherapy in physical sequelae of SARS-CoV-2 infection: A case report. (2022)
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); few people (17 in all).
Compared with another group, not randomised17 in the study · at baseline (M0) and at 1 month (M1) at the end of intervention · three physiotherapy sessions per week for 4 weeks
No clear difference in fatigue.
The evidence is very uncertain about the effect of Physical therapy / physiotherapy on fatigue in long COVID. Little or no difference · very low certainty D
Studies with no comparison group1 in the study · 5 weeks · first 3 visits (few people)
Fatigue improved.
The evidence is very uncertain about the effect of Physical therapy / physiotherapy on fatigue in long COVID. Improvement · very low certainty C
Patients who did not have appropriate equipment and/or internet connection to participate in the program by videoconferencing followed a traditional physical rehabilitation
Two trad-R patients did not return for post-testing.
Musculoskeletal physiotherapy in physical sequelae of SARS-CoV-2 infection: A case report. (2022)
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (32 in all).
Studies with no comparison group32 in the study · 4 weeks · 4-week, 20–30 min, with 3–5 sessions per week recommended
Quality of life improved.
The evidence is very uncertain about the effect of Physical therapy / physiotherapy on quality of life in long COVID. Improvement · very low certainty C
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); few people (17 in all).
Compared with another group, not randomised17 in the study · at baseline (M0) and at 1 month (M1) at the end of intervention · three physiotherapy sessions per week for 4 weeks
No clear difference in daily functioning.
The evidence is very uncertain about the effect of Physical therapy / physiotherapy on daily functioning in long COVID. Little or no difference · very low certainty D
Studies with no comparison group1 in the study · 5 weeks · first 3 visits (few people)
Daily functioning improved.
The evidence is very uncertain about the effect of Physical therapy / physiotherapy on daily functioning in long COVID. Improvement · very low certainty C
Combination: CBT and psychotherapy + Physical therapy / physiotherapy1 in the study
Case Report: Overlap Between Long COVID and Functional Neurological Disorders. (2021): returned to his studies and social activities, better (not tested).
Shown, not counted: physical therapy / physiotherapy was given together with other treatments.
Patients who did not have appropriate equipment and/or internet connection to participate in the program by videoconferencing followed a traditional physical rehabilitation
Two trad-R patients did not return for post-testing.
Musculoskeletal physiotherapy in physical sequelae of SARS-CoV-2 infection: A case report. (2022)
Why this grade: Uncertain, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); helped less than low-dose naltrexone, an active treatment; not a sign of harm.
Compared with another group, not randomised108 in the study · at least 1 month after starting treatment
Overall symptoms improved less than with the comparison treatment.
Physical therapy / physiotherapy helped overall symptoms less than low-dose naltrexone in the one comparison. Uncertain · very low certainty –
Combination: CBT and psychotherapy + Physical therapy / physiotherapy1 in the study
Case Report: Overlap Between Long COVID and Functional Neurological Disorders. (2021): mild symptoms persisted limiting physical activities, no clear difference.
Shown, not counted: physical therapy / physiotherapy was given together with other treatments.
Low-dose Naltrexone Improves post-COVID-19 condition Symptoms. (2024)
Adjusted for age, Charlson Comorbidity Index score and prior COVID-19 hospitalization.
To be included in the physical therapy group, patients needed to be receiving physical therapy and not taking any of the medications described previously.
we had incomplete data for the analysis of inflammatory markers.
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · over 30 months (few people)
Autonomic symptoms improved.
The evidence is very uncertain about the effect of Physical therapy / physiotherapy on autonomic symptoms in ME/CFS or long COVID. Improvement · very low certainty C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · over 30 months (few people)
Pain improved.
The evidence is very uncertain about the effect of Physical therapy / physiotherapy on pain in ME/CFS or long COVID. Improvement · very low certainty C
Why this grade: Uncertain, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance; one study saw it get worse, without a test against chance.
Studies with no comparison group1 in the study · over 30 months (few people)
Too little to say about cognition (brain fog).
Too little to say: cognition (brain fog) got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –
Why this grade: Uncertain, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance; one study saw it get worse, without a test against chance.
Studies with no comparison group1 in the study · over 30 months (few people)
Too little to say about fatigue.
Too little to say: fatigue got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · over 30 months (few people)
Daily functioning improved.
The evidence is very uncertain about the effect of Physical therapy / physiotherapy on daily functioning in ME/CFS or long COVID. Improvement · very low certainty C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all).
Studies with no comparison group1 in the study · over 30 months (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of Physical therapy / physiotherapy on overall symptoms in ME/CFS or long COVID. Improvement · very low certainty C
Outcomes that only studies of physical therapy / physiotherapy given together with other treatments looked at. Shown, not graded: they can’t tell what physical therapy / physiotherapy did alone.
Cognition (brain fog) Long COVID
Combination: CBT and psychotherapy + Physical therapy / physiotherapy1 in the study
Case Report: Overlap Between Long COVID and Functional Neurological Disorders. (2021): subjective cognitive complaints, better.
Shown, not counted: physical therapy / physiotherapy was given together with other treatments.
Post-exertional malaise Long COVID
Combination: CBT and psychotherapy + Physical therapy / physiotherapy1 in the study
Case Report: Overlap Between Long COVID and Functional Neurological Disorders. (2021): post-exertional malaise, no clear difference.
Shown, not counted: physical therapy / physiotherapy was given together with other treatments.
| Side effect | Studies that reported it |
|---|---|
| Fatigue | 1 study |
| Worse symptoms or a flare | 1 study |
Reviews pool earlier studies. Each shows when it was published and how far its search went.
“PR probably performs in the same way in both COPD and long-covid”
This retrospective cohort study asked whether treatments adapted from ME/CFS improve symptoms and inflammatory markers in post–COVID-19 condition at the Miami Veterans Affairs post–COVID-19 clinic. It included 108 patients who started PCC treatments and had at least 2 follow-up visits; the treatment groups were low-dose naltrexone (n = 24; 1.5–4.5 mg daily), amitriptyline (n = 41; 10–20 mg daily), duloxetine (n = 17; 20–120 mg daily), and physical therapy alone (n = 26). Treatment duration was not reported; improvement was defined at least 1 month after starting treatment. Median follow-up was 147 (58–264) days for low-dose naltrexone, 250 (120–310) days for amitriptyline, 174 (36–241) days for duloxetine, and 101 (43–152) days for physical therapy. Improvement in at least 1 of fatigue, pain, brain fog, or dyspnea was reported by 67% taking low-dose naltrexone, 61% taking amitriptyline, 41% receiving physical therapy alone, and 35% taking duloxetine. The adjusted relative hazard of improvement for low-dose naltrexone versus physical therapy alone was 5.04 (95% CI, 1.22–20.77; P = 0.02). Amitriptyline (2.68; 0.80–8.97; P = 0.10) and duloxetine (0.82; 0.17–3.85; P = 0.81) did not significantly improve over physical therapy. Symptom reports: low-dose naltrexone for fatigue and pain; amitriptyline and duloxetine for fatigue; physical therapy for dyspnea and fatigue. The text states low-dose naltrexone decreased C-reactive protein and increased cortisol and other treatments did not, while Table 4 also lists changes for duloxetine; all biomarker changes were nonsignificant (P > 0.05). Harms and withdrawals were not reported.
This nonrandomized controlled pilot study enrolled 17 patients (nine men and eight women) with post-COVID-19 fatigue for <3 months after hospitalization in a COVID-19 unit at Saint-Etienne Hospital, recruited from March to July 2021. Patients were assigned to tele-R (n = 9) or trad-R (n = 8). Tele-R was 12 supervised personalized exercise sessions and three therapeutic education workshops over a 4-week training program; trad-R was three physiotherapy sessions per week for 4 weeks. Outcomes were assessed at baseline (M0) and at 1 month (M1). The primary outcome was CFS-11. Data were collected on nine tele-R and six trad-R patients; two trad-R patients did not return for post-testing. CFS-11 was reduced in both groups (tele-R 25.2 ± 5.3 vs. 21.1 ± 5.1; trad-R 27.6 ± 4.2 vs. 26.2 ± 5.2), with a significant time effect (p = 0.010) and no difference between groups. VO2max improved by 3.8 points (+18 ± 15%) in tele-R and 4.1 points (+17 ± 19%) in trad-R (p = 0.005); ΔVO2, ΔMAP, ΔVT1, and Δ6-WMT were not significantly different between groups. Handgrip was not improved (9 ± 16 vs. 2 ± 16%, p = 0.400). No adverse events were declared. The authors state the sample was reduced, there was no control group without rehabilitation and no randomization, and a larger study would be necessary.
This cross-sectional follow-up survey asked patients with long COVID seen at a post-COVID clinic (PCoCC) about symptoms and treatments. A total of 852 patients were identified; 536 completed the survey. The mean time from COVID-19 infection to survey completion was 23.2 ± 6.4 months. There was no comparison group; patients rated symptoms at the initial clinic visit (baseline, by recall) and at follow-up on a 1-10 scale, and rated whether treatments were helpful. Surveyed treatments included low-dose naltrexone, vagal nerve stimulator, midodrine, fludrocortisone, pyridostigmine, aripiprazole, plasmapheresis, reishi mushroom and nattokinase/serrapeptase; treatment duration was not reported. Overall functioning median improved from 8 (6, 9) at baseline to 5 (3, 8) at follow-up (P < .001); fatigue improved from 8 (7,10) to 6 (3, 8) and brain fog from 8 (6, 9) to 5 (3, 8) (P < .001 for both). All individual symptoms assessed were significantly improved (P < .001). Only 4.5% (24/536) had recovered completely. Helpful ratings included low-dose naltrexone 45/77 (58%), vagal nerve stimulator 18/34 (53%), plasmapheresis 9/9 (100%), midodrine 7/17 (41%), fludrocortisone 8/17 (47%), pyridostigmine 2/3 (67%), aripiprazole 8/17 (47%), reishi mushroom 8/19 (42%) and nattokinase/serrapeptase 5/9 (56%). A minority worsened in overall function and in fatigue, myalgia and orthostasis; counts, side-effect counts, and withdrawals due to harms were not reported.
This pre-post clinical trial enrolled 32 adults with Long COVID syndrome, recruited through non-probabilistic sampling from various health centres in Andalusia during 2022. Participants received a 4-week personalized digital physiotherapy program sent by email, with a recommended session duration of 20–30 min and 3–5 sessions per week depending on fatigue and/or dyspnoea. There was no comparison group. Quality of life was assessed with the SF-12 and EuroQoL-5D, and satisfaction and perception with the Telemedicine Satisfaction Questionnaire plus four open-ended questions. A total of 32 participants completed the 4-week intervention and were included in the analysis. After the intervention, the SF-12 physical component increased by 4.04 points (from 26.42 to 30.46) and the mental component by 6.55 points (from 43.52 to 50.07); p = .001. The total mean TSQ score was 65.25 ± 6.02. All participants found the personalized digital physiotherapy program helpful, and patients reported no adverse effects during the intervention. The authors state limitations including the small sample size (n = 32) and the short 4-week duration, and note that randomization was not used.
This single case report describes a 35-year-old female with a 6-year history of ME/CFS who was referred for evaluation regarding plasma exchange therapy. After SARS-CoV-2 infection in 2022 she had transient post-exertional malaise and persistent brain fog and concentration difficulties; raltegravir, started in 2020, was gradually tapered and discontinued during treatment. In January 2024 therapeutic plasma exchange was initiated using the Terumo Optia system with peripheral venous access, each session a 1:1 plasma volume exchange with 5% albumin (3500 mL) and citrate anticoagulation; Table 2 lists nine procedures in total, every 2–4 months, while the text says plasma exchange was initially performed every 2–3 months. Low-dose intravenous immunoglobulin (OCTAGAM) was administered at the end of each cycle. The patient reported marked improvement in fatigue, concentration and cognitive clarity, and at 3 months and 6 months follow-up no signs of symptom recurrence; she also reported improved stamina, weight loss and disappearance of menstrual cycle–related symptom exacerbations. Regular blood gas analyses during the procedures revealed recurrent hypocalcemia as a side effect of citrate anticoagulation, corrected with intravenous calcium, although the paper also states the therapy was well tolerated, with no reported side effects or complications. Antibody levels three months and one month before and 6 months after the first plasma exchange are given in Table 1.
This case report describes a single male patient in his 30s with a co-diagnosis of ME/CFS and MS, followed longitudinally. After a new MS relapse with radiological inflammation, he received rituximab at 1 g on days 1 and 15 of the first month, then nine monthly doses of 1 g adjusted by B-cell repopulation, a 9-month treatment regime. There was no comparison group; outcomes were before-versus-after observations in this patient. The report states a significant improvement in fatigue after the third dose, enabling increased mobility and participation in daily activities such as walking and dining out. On the Bell scale for severity assessment, the patient changed from a level of 10 to 20. After treatment he could leave the house 2–3 times a week and take gentle walks for an hour, and he reported a migraine once a month. The authors report he stayed in remission for at least 3 years after treatment. Harms of rituximab were not reported. The authors note limitations including sub-optimal frequency of MRI to monitor lesion progression and of HERV reassessment after rituximab, and the limited external validity of single study cases.
This case study reports a 19-year-old male who developed impairment consistent with ME/CFS after SARS-CoV-2 infection. The study reports one patient; there was no comparison group, and outcomes were before-versus-after over 30 months. Treatment included physical therapy; stationary biking and running as graded activity; oral sodium chloride and lower limb compression garments; and medications/supplements: fludrocortisone, midodrine, atenolol, pyridostigmine bromide, ivabradine, clonidine, methylphenidate, fexofenadine, famotidine, cromolyn, quercetin, escitalopram, and naltrexone. The paper reports significant improvement in symptoms over 30 months. With cromolyn, peak walking heart rate fell from the 130–140 bpm range to 100–105 bpm. Stopping fexofenadine and famotidine was accompanied on more than one occasion by increased fatigue and cognitive dysfunction; stopping H1 and H2 antihistamines was associated with worsened concentration and short-term memory. Naltrexone was associated with improved energy and overall function, and the patient reported improvements with low doses of clonidine and methylphenidate. For the first 15 months after infection, he continued to have exercise intolerance, with heart rate reaching 130–150 bpm during each of two 15-min walks daily. At one year, remaining symptoms included daily fatigue; lightheadedness and headaches were infrequent. He later resumed running at 10 min four times a week, increased running by two minutes each week, and in October 2022 competed in an 8 K event. Adverse effects were reported with fludrocortisone, midodrine, atenolol, pyridostigmine bromide, and ivabradine. Limitations stated include possible spontaneous improvement and uncertainty about independent effects of interventions.
This case report described one 17-year-old girl referred to a pulmonary out-patient clinic two months after positive SARS-CoV-2 testing with severe post-acute Covid-19 symptoms. She received methylprednisolone 1 g per day over five days, plus daily physiotherapy including breathing guidance, counselling by a psychologist and a dietary adviser. There was no comparison group; outcomes were observed before and after treatment. The report described clinical symptoms, remaining symptoms at follow-up two weeks and three months after discharge, and dyspnoea and pulmonary restriction under physiotherapeutic training. Clinical symptoms regressed rapidly after the five-day course of methylprednisolone; therapy was well tolerated and showed prompt improvement in all relevant areas; the patient remained asymptomatic after rehabilitation treatment; follow-up examinations gave no evidence for remaining clinical symptoms; and symptoms were rapidly and almost completely regressive under methylprednisolone. Perceptible improvement of dyspnoea and pulmonary restriction under physiotherapeutic training was also reported. The authors state that rare post-infectious conditions like this are hardly recognized, and that long-term bed confinement and weight loss may have contributed to the reduced condition at hospitalization.
This case report followed one patient (patient 3 from a 2018 case series) with ME/CFS, orthostatic intolerance, and cervical spinal stenosis; there was no comparison group. The patient first received decompression at C5-C6 and disc replacement. Treatment duration was not reported; follow-up after the second surgery extended to a 9-month point. Outcomes included Karnofsky Performance, SF-36 physical function, Wood Mental Fatigue Inventory, and clinical symptoms. After the first operation, the authors reported resolution of tremor, headache, and right shoulder and neck discomfort in the first post-operative week; symptom-free standing tolerance improved to 45 min; and at 7 months she could engage in vigorous exercise without developing PEM. Later, symptoms returned, including fatigue, cognitive dysfunction, myalgias, need for a motorized wheelchair for longer distances, and increased lightheadedness and heart rate when squatting and standing. Imaging showed a several millimeter shift of the C6 implant plate and a 33.1% reduction in cervical canal diameter. She then received removal of the original disc replacement implant at C5-C6, revisional decompression at C5-C6, and interbody arthrodesis. At 2 months after the second operation she reported increased energy levels and was fully functional with activities of daily living; by 6 months she reported complete resolution of neck and arm pain and improvement in lightheadedness and other ME/CFS symptoms. The authors reported significant improvement in myelopathic symptoms, lightheadedness, post-exertional malaise, and anxiety levels, and striking improvement in SF-36 PF, Karnofsky Performance, and Wood Mental Fatigue Inventory scores. Harms counts and withdrawals due to harms were not reported.
This case report described one 60-year-old woman diagnosed with mild COVID-19 in July 2020 in Pisco, Peru, who had physical sequelae. She received musculoskeletal physiotherapy at home over 5 weeks in 15 visits. Components included Transcutaneous Electrical Nerve Stimulation for 20 min in the first 3 visits, Cyriax deep transverse massage, passive, active free and resisted kinesitherapy with weights of 1/2 kg, 1 kg and up to 2 Kg, stretching exercises, the Maitland manual therapy technique, and balance and coordination exercises. There was no comparison group. The report measured pain on the Numerical pain scale (0–10), muscle strength on the Daniel Scale, joint ranges according to AAOS, the Unipodal Station Test, and BADLs/IADLs. At the end of the fifteenth visit, the Numeric Pain Scale decreased from 10/10 to 3/10; muscle strength improved from 2/5 to 4/5; initial joint ranges were expanded from 67% to 100%; and single-leg standing time changed from 3 s to 8 s. The patient was able to perform BADLs and IADLs, no longer felt fatigue or weakness, and regained appetite and usual body weight. Some ranges were unchanged: left shoulder adduction 30° to 30°, left external rotation 80° to 80°, left internal rotation 60° to 60°, and elbow extension right and left 0° to 0°. Harms and withdrawals were not reported. The authors stated their results cannot be generalized.
This case report describes one 61-year-old non-smoking man with obesity and well-controlled intermittent asthma who developed severe COVID-19 pneumonia in June 2020, complicated by acute respiratory distress syndrome and pulmonary embolism, requiring intensive care and high-flow oxygen therapy. During the acute illness he received intravenous methylprednisolone 100 mg per day, dexamethasone 6 mg per day for 10 days, enoxaparin and Optiflow oxygen. He was discharged home with oxygen at 6 L/min. After discharge he had cough, resting and exertional dyspnea, and a chest CT scan showed bilateral interstitial lung lesions; superinfection was ruled out by bronchioalveolar lavage. He was then treated with oral prednisolone 0.5 mg/kg/day at a digressive dose (50 mg/day for 1 month, 40 mg/day for 2 weeks, 30 mg/day for 2 weeks, 10 mg/day for 2 weeks, and finally 5 mg for 2 weeks), about 3 months in total. The report describes improvement of the lung disease, a fall in oxygen requirements to 4 L/min and then 2 L/min with weaning at the end of August 2020, normalization of respiratory function, and return to daily activities at the beginning of September 2020. TLC rose from 39 to 89.7, FVC from 1.78 to 2.81 L and FEV1 from 1.37 to 2.30 L. There was no comparison group. He developed stress and anxiety and refused oxygen therapy. The authors state the efficacy of such treatment requires validation by randomized trials.
This case report describes one 24-year-old female professional athlete with post-acute sequelae of COVID-19 (PASC) after a mild SARS-CoV-2 infection. She was diagnosed in the Department of Pneumology at the Bundeswehr Hospital in Ulm in July 2022 and received step-by-step treatment at the same clinic until March 2023. The multimodal therapy concept included azithromycin 250 mg 3 days a week for 3 months; anti-obstructive inhalation therapy with indacaterol/mometasone 125/260 μg, escalated after 6 weeks to glycopyrronium/indacaterol/mometasone 46/136/114 μg; 3 sessions of bronchial thermoplasty; and myoreflex therapy every 14 days. There was no comparison group; outcomes were compared before and after treatment. Lung function and spiroergometry were measured. After 3 months, significant improvements were registered. A functional follow-up 3 months later confirmed significant clinical and functional improvements. Table 1 reported FVC 91 to 102, FEV1 74 to 99, Tiffeneau-Index 68 to 83, MEF50 51 to 92, TLC 131 to 110, RV/TLC 163 to 93, DLCO 107 to 105, KCO 106 to 107, power 130 to 205 watts, VO2max 81 to 108, and oxygen pulse 107 to 126. The authors also reported complete remission of pulmonary PASC within 35 weeks and a successful qualification for the Paris Olympic summer games in June 2024. Harms and withdrawals were not reported. Limitations were not reported.
This prospective cohort study, conducted in four medical centers, evaluated long-term outcomes of rehabilitation programs in patients with long COVID syndrome. A total of 120 patients were included, and 113 patients (aged between 21 and 85, mean age 58.4 years) completed the study; 7 patients (5.83%) dropped out. The experimental group (n=25) received a tailored multidisciplinary program of 7-8 sessions including aquatic exercises, respiratory and motor exercises, social integration training, neuropsychologic sessions, LASER therapy and magnetotherapy. Comparison group 1 (n=25) received 7-8 sessions of eastern medicine techniques; comparison group 2 (n=29) received respiratory and motor exercise therapy physiotherapy, inhalation of mineral water, balneotherapy with dry carbon dioxide baths and magnetotherapy for 10-15 sessions; comparison group 3 (n=34) performed self-training and home-based physical exercise. A structured telephone contact after 6 months ± 7 days from the end of rehabilitation recorded hospital admissions, deaths, disability, specialist consultations and ambulance calls. The patients in the comparison groups were more likely to request therapeutic care (χ2=6.635, p=0.001; χ2=13.463, p=0.001; χ2=10.949, p=0.001) and more likely to be hospitalized (χ2=5.357, p=0.021; χ2=0.125, p=0.724; χ2=0.856, p=0.355) than the EG. Hospital admissions were 1 (4.00%) in the EG, 7 (28.00%) in CG1, 2 (6.90%) in CG2 and 4 (11.76%) in CG3. The RR of hospital admissions was 0.143 (CI: 0.019; 1.078) versus CG1, 0.580 (CI: 0.056; 6.022) versus CG2 and 0.340 (CI: 0.040; 2.860) versus CG3; the RR was reduced by 85.7%, 42.0% and 66.0%, respectively. General practitioner consultations were 4 (16.00%) in the EG versus 17 (68.00%), 19 (65.52%) and 20 (58.82%) in the comparison groups. There were no patient deaths or new onset of disability in any analyzed group. The authors state future studies will need to further investigate these aspects.
This case report describes one 72-year-old female with long COVID after COVID-19 infection, treated in a neurological day hospital and a psychiatric inpatient unit and followed as an outpatient. There was no comparison group. Between June 17 and July 8 2022 she was treated in a neurological day hospital without improvement in her health status. She then received outpatient psychiatric help and antidepressant therapy with sertraline 50 mg per day and mirtazapine 15 mg per day for almost 2 months, without significant improvement in her condition. In the psychiatric inpatient unit, between August 29 and September 23, 2022, she received venlafaxine up to 75 mg per day, trazodone up to 50 mg in the evening, nutritional supplements, enteral feeding, and non-drug therapy (visual art, music, drama, dance and movement therapy, occupational therapy, psychotherapy, physiotherapy). At hospitalization, PHQ-9 was 21 and CGI-S was 6; at discharge PHQ-9 was 8, CGI-S 3, and CGI-I 2. At the last outpatient follow-up visit on 01/5/2023, PHQ-9 was 5, CGI-S 3, and CGI-I 2. Mood, energy, anxiety, and sleep improved, but rapid fatigability, difficulty concentrating, unclear thinking, forgetfulness, and brain fog persisted; weight remained 48 kg with no weight gain, and she remained unable to resume work. Side effects and withdrawals were not reported.
This case report describes one patient, a 23-year-old man who developed fatigue, episodic shortness of breath, nocturnal tachycardia, chest pain, attention and memory difficulties, fluctuating limb dysesthesia, and left arm weakness after asymptomatic COVID-19. He was evaluated at a post-COVID center and received a diagnosis of post-COVID-19 syndrome; after neurological examination, a diagnosis of functional neurological disorder was made, and he was referred to the authors' center for FNDs. The patient received psychoanalytic psychotherapy and targeted physical therapy for 4 months. There was no comparison group. Outcomes described were dysesthesia, motor symptoms, subjective cognitive complaints, return to studies and social activities, physical activity, post-exertional malaise, chest pain, and fluctuating muscle tension. After 4 months, dysesthesia and motor symptoms had resolved, and subjective cognitive complaints had improved significantly. The patient returned to his studies and social activities but had not fully resumed physical activity. Post-exertional malaise, chest pain, and fluctuating muscle tension in his back and left arm persisted. The patient had not fully recovered, as mild symptoms persisted limiting physical activities. Side effects were not reported. The authors do not report a formal limitations section.
This single-cohort retrospective study with a follow-up survey investigated symptomatic treatment use and patient-reported improvement in post-COVID syndrome. It included 200 patients attending the post-COVID center of the University Hospital of Erlangen between December 2022 and July 2023, with symptoms persisting at least three months after SARS-CoV-2 infection; vaccine-related symptom onset was excluded. Baseline records captured symptomatic therapies from three months post-infection until presentation. A follow-up questionnaire was completed by 165 patients (response rate 82.5%), a mean 6.3 months (SD = 2.2) after initial consultation. Treatment duration was not reported. There was no control group; patients rated improvement within the same cohort for each therapy they used, using 0 = no improvement to 3 = very strong improvement. Among therapy users, strong to very strong improvement was reported by 12 of 38 for beta-blockers, 8 of 27 for antibiotics, 5 of 15 for plasmapheresis, and 8 of 73 for outpatient psychotherapy. Vitamins and nutritional supplements were rated 9 of 135. No between-group comparison was reported. Harms, side effects, worsening and withdrawals were not reported. The authors state that the study gives initial insights into utilization and patient-reported symptom improvement.
This systematic review asked whether treatments for long COVID improve outcomes. It searched MEDLINE through PubMed from 2020 to August 2024 and included 43 randomized clinical trials of people with long COVID. The trials compared interventions with control groups or other treatments and reported a primary outcome. Treatments included nutraceuticals, respiratory muscle training, supervised exercise or pacing, brain stimulation, and medications. Outcomes included symptoms, exercise capacity, Vo2 max, fatigue, cognitive functions, inspiratory pressure, pain, and olfactory and gustatory function. The review reports that all studies testing supervised exercises improved the primary outcome except for one; all but one brain stimulation study improved the primary outcome; and only 2 studies using medications improved the primary outcome. Nirmatrelvir/ritonavir did not improve symptoms; donepezil and lithium did not improve their primary outcomes; thermal water inhalation and a metabolic modulator did not improve the primary outcome. Creatine improved fatigue; vitamin C improved exercise capacity; inspiratory muscle training improved symptoms, exercise capacity and inspiratory pressure. Reported harms included 33% with adverse events (dry mouth) with amantadine, 16% nausea with creatine, 17%–37% adverse events with TMS, two to four percent TMS discontinuation, and 8% inspiratory muscle training discontinuation. The authors state the evidence was mostly low certainty.
This systematic review and meta-analysis asked whether physiotherapy treatments reduce persisting dyspnoea in long COVID. The reviewers searched MEDLINE, PEDro, WOS, Scopus, VHL and the Cochrane Library for studies published between September 1st, 2019 and July 2nd, 2023; the protocol was registered as CRD42023427464. They included comparative trials of adults with persistent breathlessness following COVID-19, regardless of initial severity, in whom physiotherapy was implemented as treatment for dyspnoea. 19 studies including 1292 adults fulfilled the inclusion criteria. Treatments were grouped as high-intensity rehabilitation, low-to-moderate intensity rehabilitation, respiratory muscle training, and other/passive techniques; dyspnoea was assessed with dyspnoea-specific, functional, or health-related quality-of-life scales. The authors report that physiotherapy and especially pulmonary rehabilitation may help alleviate respiratory symptoms. They state that high-intensity rehabilitation shows particularly more promising results than low-to-moderate rehabilitation or respiratory muscle training, whereas results for low-to-moderate intensity and respiratory muscle training groups were non-significant. For low-level laser therapy, the review states it seems to have significantly reduced dyspnoea and markers of inflammation in people with long-covid. The recorded data include no side-effect, worsening, or withdrawal counts. The authors state limitations including heterogeneity of interventions and controls, risk of bias from open or assessor-only blind studies, and short-term follow-up.
This systematic review included eight randomised controlled trials of exercise interventions in adults with long COVID, conducted in Spain, France, Turkey, China and Poland. Follow-up periods ranged from 2 to 28 weeks (mean=8.5 weeks); sample sizes ranged from 39 to 119 (mean=56). Interventions included supervised strength and aerobic exercise, telerehabilitation with aerobic exercise, breathing exercises plus a walking programme, virtual reality aerobic exercise, and hospital-based pulmonary rehabilitation. Comparators included a WHO self-management leaflet, short educational instructions, a brochure, no treatment, standard physiotherapy, in-person versus virtual reality exercise, and home-based versus inpatient rehabilitation. Outcomes included dyspnoea, fatigue, physical function, HRQoL, mental health and general symptoms. The review reports short-term improvements in dyspnoea, fatigue, physical function and the physical domain of HRQoL, with no between-group differences in some outcomes including anxiety and depressive symptoms and ME/CFS symptoms. Of five studies reporting adverse events, four recorded none; one reported no serious adverse events but more mild adverse events in the intervention group in the first 6 weeks, mostly chest tightness, weakness or reduced strength, and cough. One of 252 participants discontinued exercise due to tolerance-related issues (chest pain); in the eighth study, 1 of 26 discontinued, reason not provided. The authors state the evidence base is limited by small sample sizes and short follow-up.
This systematic review asked whether physical exercise changes functional physical performance in people with long coronavirus disease-2019 (COVID-19). Seven studies were reviewed; interventions lasted 2 to 16 weeks, with frequencies of 2 to 7 days per week. Search databases included MEDLINE, EMBASE, Web of Science, Scielo, SPORTDiscus and CINAHL. The included studies compared exercise programmes with control conditions such as standard physiotherapy, usual care, home rest, medical care and advice, or home-based guidelines. Outcomes covered strength, cardiorespiratory fitness, agility/mobility, anxiety, depression, quality of life, dyspnea and fatigue. Strength improved in 67% of studies, cardiorespiratory fitness in 50%, and agility/mobility in 60%. Anxiety improved in 25% of studies, depression in 75%, and quality of life across all studies (5 out of 5). Dyspnea improved in 40% and fatigue in 80% of studies. Adverse effects were assessed in five studies, which did not report their occurrence. Worsening and stopping were not reported. The authors conclude that results suggest potential benefits of exercise training in several outcomes, mainly functional capacity, depression symptoms, quality of life and fatigue. They state limitations: the studies evaluated show a varied population, including hospitalized and non-hospitalized individuals; the absence of a standardized therapeutic protocol with interventions of varying duration makes it difficult to understand the effects; and the small sample size restricts generalization and the ability to detect significance.
This systematic review with meta-analysis asked whether rehabilitation interventions help adults with COVID-19 or post COVID-19 condition (PCC). It included 40 studies with 2445 participants; patients were adults hospitalized in any setting or discharged at home, with any COVID-19 severity or PCC. Interventions included pulmonary rehabilitation, self-activities, qigong exercise and acupressure rehabilitation program (QARP), yoga and naturopathy, Mandala coloring, cognitive motor training, and FES-cycling. Comparisons were usual care or no intervention. Pooled analyses compared pulmonary rehabilitation with usual care in post COVID-19 patients: exercise capacity favored pulmonary rehabilitation (MD 65.06, 95% CI 42.87 to 87.25; 2 studies, 184 participants); FEV1 favored pulmonary rehabilitation (MD 0.16, 95% CI 0.05 to 0.28; 2 studies, 179 participants); FEV1/FVC favored pulmonary rehabilitation (MD 0.05, 95% CI 0.01 to 0.09; 2 studies, 174 participants); FVC showed no effect (MD 0.19, 95% CI -0.03 to 0.42; 2 studies, 179 participants). Self-activities plus usual care compared with usual care showed an anxiety effect (MD -12.03, 95% CI -21.16 to -2.90; 2 studies, 207 participants). Narrative findings said QARP and “twist and raise” walking technique seem to reduce dyspnea and weakness; yoga and naturopathy, Mandala coloring, and respiratory exercise seem to reduce anxiety and depression; cognitive motor training seems to improve cognitive function; FES-cycling seems useful for erect position restoration and walking capacity. Li 2022 reported no serious adverse events; another study reported headache and dizziness events but no significant difference between groups. Worsening or stopping was not reported. The authors state very uncertain evidence and very low certainty.
This systematic review asked whether rehabilitation treatments applicable in ambulatory care help adults with persisting symptoms after COVID-19. Searches on 9 May 2022 identified 45,479 records, and 38 studies comprising 2,790 participants were included. Interventions included physical training, breathing exercises, nutritional supplements, olfactory training, multidisciplinary treatment, and other treatments such as hyperbaric oxygen therapy; treatment duration was not reported. Comparisons varied, including low- versus high-intensity training in 76 men and advanced versus classical olfactory training in 80 patients. Outcomes included fatigue, dyspnoea, pain, physical capacity, pulmonary function, sensory function, quality of life, return to activities, functional capacity, and adverse events. Physical training and breathing exercises may reduce fatigue, dyspnoea, and chest pain and may improve physical capacity and quality of life, with very weak evidence; improvement was not demonstrated for muscle pain or return to work. Low-intensity training increased handgrip strength and quality of life compared with high-intensity training. Advanced olfactory training was not superior to classical training. Hyperbaric oxygen therapy can have beneficial effects on fatigue in one cohort of 10 patients. Side effects with olfactory training occurred in 18 out of 80 participants. Reported adverse events included hospitalisations, dizziness, symptom exacerbation such as fatigue, headache in one participant, and post-exertional malaise after exercise.
This systematic review asked whether physical therapy treatments for chronic fatigue syndrome have support from randomized controlled trials. The authors searched MEDLINE, Cochrane Library, and PEDro, and required randomized controlled trial design, English publication, and a publication window stated in the abstract. Four studies were included, and the studies were evaluated with the Jadad score. The abstract does not name the participants' location, the number of people enrolled or analysed, the treatment dose or duration, or the comparator used in the included trials. It reports no numerical results of the included studies, no side effects, and no withdrawals. The review suggests that a treatment that is more effective than all the others cannot be defined. The authors write: “This conclusion is related to the low number of investigated studies; therefore, the collected results cannot be generalized.” In the conclusion, the authors state that rehabilitation programs that promote physiotherapy techniques such as exercise, mobilization, and body awareness (e.g., MRT and GET) are the most effective in reducing medium and long-term fatigue severity in CFS patients. They also state that chronic fatigue syndrome is not yet a well-understood pathology and that physical mechanisms influencing outcomes still need more study.
This review examines low-dose naltrexone (LDN) for chronic pain, fibromyalgia, and post-COVID chronic fatigue syndrome/long COVID, noting similarities between long COVID and ME/CFS. It summarizes small studies: in long COVID, Bonilla et al (n=59) reported significant reduction in number of symptoms and FSS scale (P<0.002); Isman et al (n=31) reported mean total SF-36 improved from 36.5 to 24.8 at wk 12 (P<0.0001); Tamariz et al (n=108) reported self-reported improvement 67% with naltrexone, 61% with amitriptyline, and 41% with physical therapy; O’Kelly et al (n=36) reported significant reduction in all symptoms (P<0.05). In fibromyalgia, Abou-Raya et al (n=74) reported VAS change −20.1 with LDN and −10.7 with placebo (P<0.001); Bested et al (n=58) found FIQR difference 1.65 (P=0.3) and SPIR 0.33 (P=0.4); Bruun et al (n=99) found pain intensity change −1.3 with LDN and −0.9 with placebo (P=0.27); Younger et al (n=10) reported self-rated symptoms reduced 32.5% with LDN and 2.5% with placebo (P=0.003). In chronic pain, Beaudette-Zlatanova et al (n=23) found BPI difference −0.3 (P=0.22); Tsui et al (n=45) found no difference in pain severity versus placebo (P=0.55). Reported adverse effects include nausea, sleep disturbances, nightmares, and vivid dreams. No counts of worsening or discontinuation were reported. The authors state evidence is limited by small sample sizes and study design biases.
This rapid review examined the role of occupational therapy for adults and older adults with long COVID across the healthcare continuum. It included Twenty-one articles. The review reports no comparison group and was not randomised. Reviewed occupational therapy interventions were mainly delivered in rehabilitation settings and included retraining in activities of daily living, cognitive rehabilitation, physical and breathing exercises, patient education, return-to-work planning, and psychosocial support. One included trial randomised 64 participants to two groups (n = 32 in each group) and reported that a telerehabilitation exercise program resulted in greater improvements on perceived physical exertion at rest and after physical activity. In another included study, post-course participants reported 53.9% improved health state, 7.9% no change, 10.5% worse health state, and 22.4% mixed change. In a telerehabilitation cohort of 34 enrolled, 30 completed; 63% still experienced post-exertional malaise, only four participants were able to work full-time, and fatigue and health-related quality of life did not statistically or clinically meaningfully improve. An energy management study of 17 participants found the SF36 mental component showed no significant changes. The authors state limitations including potential to miss articles, most studies from North American and European countries, and that most studies were pilot, feasibility, and case studies that lacked power and were heterogeneous.
This scoping review asked what physiotherapy interventions and treatment parameters have been published for post- and long-COVID-19. The authors searched PubMed, EBSCO, Scopus, Web of Science, Embase, PEDRO, Cochrane and WISO in March 2023 and included 6 studies; they state no published study focusing on long-COVID-19 was identified. The included studies covered respiratory therapy, aerobic training, strength training, and in a study ‘hands-on’ physiotherapy. Comparisons varied: some randomised trials compared training or breathing interventions between groups, while case reports described before-and-after courses. Reports included 60 patients (31 female, 29 male), 52 men, 65 men, 32 patients (20 female, 12 male), and case reports of a 37-year-old woman and a 60-year-old woman. Measured outcomes included fatigue, walking distance, dyspnoea, quality of life, muscle strength, lung function and adverse events. Reported changes included fatigue reduction, for example Nagy study group from 43.36 to 28.68 and control group from 42.47 to 39.77, and walking distance increases, for example Rutkowski VR group from 502 to 558 m and control group from 512 to 552 m. Muscle mass and lung function were reported as unchanged; one case report reported decreased quality of life. The authors state treatment descriptions were often inadequate and the data were summarised descriptively, limiting conclusions about effectiveness.
This narrative review synthesized evidence from 97 studies (n=8260, 103 publications) on interventions for common long COVID symptoms: fatigue, neurocognitive symptoms, anxiety, depression, and sleep issues. The review included randomized and non-randomized studies and compared medications, rehabilitation, behavioral and mind-body programs, supplements, complementary treatments, and COVID-19 vaccination with placebo, usual care, no treatment, or other active comparators. For vortioxetine versus placebo, one RCT (n = 141) reported a significant reduction in depression symptoms (adjMD of −1.52; 95% CI −2.85 to −0.19) and improvement in quality of life (WHO-5, adjMD of 2.36; 95% CI 0.77 to 3.94), with mixed cognitive results. An RCT of “Fit after COVID” CBT (n=114) reported improvement in fatigue (CIS-fatigue: MD −8.8; 95% CI −11.9 to −5.8), cognitive impairment (CIS-concentration: MD −5.1; 95% CI −6.9 to −3.4), and physical function (SF-36-Physical Health: MD 7.1; 95% CI 2.9 to 11.3). Hyperbaric oxygen therapy (n=73) improved fatigue (SF-36 energy subscale, 18.2 vs 6.0, p=0.029) and sleep quality (PSQI, 8.1 vs 9.2, p=0.042) versus sham. Transcranial direct current stimulation (n=47) reduced physical fatigue (MFIS-Physical: p=0.034) but not overall fatigue (MFIS-Total: p=0.184). A COVID-19 vaccine study (n=453) found no statistically significant difference in fatigue, depression, or sleep quality. Adverse events included treatment-related reactions with vortioxetine (26.8% vs. 22.1%), non-serious adverse events with AXA1125 (RR 2.62, 95% CI 1.00 to 6.89), and similar adverse event rates with SIM01 (10% vs. 11%; p=0.63).
This scoping review examined health care for patients with Long Covid-19. It included 13 studies identified in electronic databases, carried out in several countries and published in English. Included studies reported telerehabilitation with physical exercises, physical exercise interventions, outpatient pulmonary rehabilitation, standard physical therapy, cognitive behavioral therapy with antidepressants and non-benzodiazepine tranquilizers, and supervised concurrent training with or without inspiratory muscle training; an exercise intervention was reported at 8 weeks. Some studies compared supervised therapeutic exercise with a WHO self-management rehabilitation leaflet, physical training rehabilitation with standard physical therapy, and physical exercise with breathing training and controls. Outcomes included physical capacity, quality of life, symptoms, fatigue, dyspnea, and stress, anxiety and depression. The review reports improvements after telerehabilitation in physical capacity, quality of life, fatigue and dyspnea; improvement in fatigue after physical intervention; reduction in dyspnea after 8 weeks of physical exercise; increase in 6-minute walk distance and decrease in dyspnea after outpatient pulmonary rehabilitation; maximum inspiratory mouth pressure increased by 28%; MDP score after physical training rehabilitation was 42% lower than after standard physical therapy; and improvement in stress, anxiety and depression with CBT plus antidepressants and tranquilizers. It also reports that some fatigue and quality of life results did not show significant improvements compared to the control group, and that participants reported relapses when performing physical exercise. No side-effect counts were reported. The authors state the selected studies did not provide specific guidelines and that there is a clear gap in the literature on how to identify and clinically manage people with this condition.
This overview examined current literature on the role of physical therapy (PT) in managing post COVID-19 related conditions and common symptoms in adults, and potential guidelines for outpatient rehabilitation. The authors searched PubMed, CINAHL, Medline, and Cochrane for English, peer-reviewed original articles on adults with post-acute COVID-19 infection and relevant PT interventions. The overview does not report the number of included studies, the number of patients, a comparison group, randomisation, setting, treatment duration, follow-up, or harms. The recorded data show no comparison group and no randomised design. The authors report a key theme that PT services helped improve overall functional mobility and symptom management in patients after an acute infection of COVID-19. They also state an essential consideration is keeping interventions specific to the patient and their goals while preventing exacerbations of symptoms. No side effects, withdrawals, or worsening were reported in the recorded data. The authors conclude that PT has a growing role in managing post COVID-19 deficits and long COVID sequelae, and that physical therapists can improve patients’ functional mobility and post COVID-19 disease management by choosing appropriate parameters and being aware of varying symptomology. They state future studies should focus on more specific interventions and finding the most effective treatment strategies.
This literature review asked how exercise testing and respiratory rehabilitation are used in long COVID, defined as persistent symptoms at 4 weeks after SARS-CoV-2 infection. A systematic search of Google Scholar covered articles published from 2019 to February 2022. The review included studies of rehabilitation after COVID-19; patients were after mild-to-critical infection, and programs included endurance, strength, respiratory physiotherapy, inspiratory muscle training, and telerehabilitation. Comparators were no rehabilitation, other rehabilitation, or non-COVID-19 rehabilitation groups. Outcomes included Barthel index, SPPB, 6-minute walk test (TM6), functional respiratory tests, DLCO, dyspnea, quality of life, anxiety/depression, hyperventilation, and V’O2. In 140 patients, median Barthel rose from 55 to 95 and SPPB from 4.2% to 66.7% predicted. In 28 patients, TM6 improved by +130 m; in another study TM6 improved +205 m versus +93 m. In 22 patients, V’O2 rose from 66% to 91% predicted at 3 months. Some studies found no significant decrease in anxiety/depression, and one found quality of life still decreased with no difference. Telerehabilitation protocols reported absence of adverse events. The authors call for more studies.
This narrative review summarized seven studies of exercise interventions in adults with post-COVID-19 syndrome (PCS), identified through MEDLINE and Scopus. Interventions included exercise training, pulmonary rehabilitation, digital physiotherapy, and blended community-based rehabilitation; reported program lengths included 6 weeks and 4 weeks. Some trials compared exercise with self-management rehabilitation recommendations or inspiratory muscle training. Outcomes included VO2max/VO2peak, maximal workload, 6MWT, SPPB, DASI, SF-12, EQ-5D-5L, and PCFS. Estimated VO2max increased by 2.1 mL/kg/min in EX and by 2.9 mL/kg/min in CT and 2.5 mL/kg/min in CTRM, with no changes in the control groups. VO2peak improved by 2.4 mL/kg/min; maximal workload by 21.8 W after 6 weeks of pulmonary rehabilitation; 6MWT by 68.9 m and 57.6 m; SPPB by +1.22 points after 4 weeks of digital physiotherapy. DASI and EQ-5D-5L increased. SF-12 physical domain showed a group effect from 35.7 to 47.8, while CT, CTRM, and RM showed pre–post increases without between-group differences; mental health increased in CTRM only from 39.5 to 44.8. PCFS < 2 changed from 3 to 14 with CT. No adverse events were reported. Dropouts were n = 6, n = 4, n = 1, and n = 3 in named studies; reasons included adherence problems, personal issues, injury and sickness, SARS-CoV-2 reinfection and fear of reinfection. Authors state no risk-of-bias and quality assessment was performed; they assume high risk of bias and low quality; heterogeneity was broad.
This Open Peer Commentary Article reviews patient survey data published between 2001 and 2015 on ME/CFS. Five major patient surveys by Action for ME and The ME Association are pooled. Surveys asked patients about availability, helpfulness, improvement, worsening, or disability benefits for therapies including GET, CBT and pacing. In Action for ME 2011a (977 respondents), 48 per cent responded ‘yes’ for GET and 66 per cent for CBT being available on the NHS, compared with 90–94 per cent for pacing, medications and fatigue/condition management. In The ME Association 2010 survey (3099 respondents), 82 per cent wanted pacing, 28 per cent CBT and 24 per cent GET. In The ME Association 2010 survey (n = 4217), 22 per cent reported improvement with GET, 26 per cent with CBT and 71 per cent with pacing; 57 per cent reported worse symptoms from GET, 20 per cent from CBT and 5 per cent from pacing. The ME Association 2015 reported a net increase in patients on disability benefits after GET courses (+13%) and CBT courses (+10%), compared with a net decrease after pacing courses (−1%). The author states survey limitations should be borne in mind.